Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FGFR1 | P11362 | 16/20 | 0.45 |
| ▸ | PDGFRB | P09619 | 13/20 | 0.45 |
| ▸ | PDGFRA | P16234 | 13/20 | 0.45 |
| ▸ | SRC | P12931 | 11/20 | 0.45 |
| ▸ | BRD4 | O60885 | 1/20 | 0.43 |
| ▸ | EGFR | P00533 | 4/20 | 0.41 |
| ▸ | FGFR2 | P21802 | 4/20 | 0.41 |
| ▸ | FGFR4 | P22455 | 4/20 | 0.41 |
| ▸ | FGFR3 | P22607 | 4/20 | 0.41 |
| ▸ | MAPK14 | Q16539 | 2/20 | 0.41 |
| ▸ | MAPK8 | P45983 | 1/20 | 0.39 |
| ▸ | PRKD3 | O94806 | 1/20 | 0.39 |
| ▸ | PRKCG | P05129 | 1/20 | 0.39 |
| ▸ | PRKCB | P05771 | 1/20 | 0.39 |
| ▸ | PRKCA | P17252 | 1/20 | 0.39 |
| ▸ | PRKCH | P24723 | 1/20 | 0.39 |
| ▸ | MAPK3 | P27361 | 1/20 | 0.39 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.39 |
| ▸ | PRKCI | P41743 | 1/20 | 0.39 |
| ▸ | PRKCE | Q02156 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14039059 | 0.87 | FGFR1 (0.48) | FGFR1PDGFRBPDGFRASRCEGFR | |
| SCHEMBL5111814 | 0.84 | FGFR1 (0.46) | FGFR1PDGFRBPDGFRASRCEGFR | |
| SCHEMBL29594951 | 0.78 | MAPK14 (0.57) | MAPK14MAPK8PRKD3MAPK1 | |
| SCHEMBL31647907 | 0.76 | FGFR1 (0.75) | FGFR1PDGFRBPDGFRASRCEGFR | |
| SCHEMBL1168005 | 0.72 | FGFR1 (0.74) | FGFR1PDGFRBPDGFRASRCEGFR | |
| SCHEMBL22532383 | 0.72 | FGFR1 (0.74) | FGFR1PDGFRBPDGFRASRCEGFR | |
| SCHEMBL31648026 | 0.72 | FGFR1 (0.56) | FGFR1PDGFRBPDGFRASRCEGFR | |
| SCHEMBL20506972 | 0.71 | BRD4 (0.57) | BRD4MAPK14MAPK8 | |
| SCHEMBL16660698 | 0.71 | BRD4 (0.62) | BRD4MAPK14MAPK8 | |
| SCHEMBL14266291 | 0.70 | MAPK14 (0.56) | BRD4MAPK14MAPK8 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7449581-B2 | 6-Substituted pyrido-pyrimidines | POCHE PALO ALTO LLC (US) | 2008-11-11 | — | — | US | disclosed |
| US-7449581-B2 | 6-Substituted pyrido-pyrimidines | POCHE PALO ALTO LLC (US) | 2008-11-11 | — | — | US | disclosed |
| US-20070135458-A1 | 6-Substituted pyrido-pyrimidines | CHEN JIAN J | 2007-06-14 | — | — | US | disclosed |
| US-20070135458-A1 | 6-Substituted pyrido-pyrimidines | CHEN JIAN J | 2007-06-14 | — | — | US | disclosed |
| US-20070135458-A1 | 6-Substituted pyrido-pyrimidines | CHEN JIAN J | 2007-06-14 | — | — | US | disclosed |
| US-7169794-B2 | 6-substituted pyrido-pyrimidines | ROCHE PALO ALTO LLC (US) | 2007-01-30 | — | — | US | disclosed |
| US-7169794-B2 | 6-substituted pyrido-pyrimidines | ROCHE PALO ALTO LLC (US) | 2007-01-30 | — | — | US | disclosed |
| US-7169794-B2 | 6-substituted pyrido-pyrimidines | ROCHE PALO ALTO LLC (US) | 2007-01-30 | — | — | US | disclosed |
| EP-1361880-B1 | 6-SUBSTITUTED PYRIDO-PYRIMIDINES | HOFFMANN LA ROCHE (CH) | 2005-09-28 | — | — | EP | disclosed |
| US-20040116698-A1 | 6-Substituted pyrido-pyrimidines | CHEN JIAN JEFFREY (US) | 2004-06-17 | — | — | US | disclosed |
| US-6696566-B2 | SELECTIVE P38 KINASE INHIBITORS RELATIVE TO CYCLIN-DEPENDENT KINASES AND TYROSINE KINASES | SYNTEX (U.S.A.) LLC | 2004-02-24 | — | — | US | disclosed |
| EP-1361880-A2 | 6-SUBSTITUTED PYRIDO-PYRIMIDINES | F. HOFFMANN-LA ROCHE AG (CH) | 2003-11-19 | — | — | EP | disclosed |
| US-20030171584-A1 | Treating p38 mediated disorders such as arthritis, Crohns disease, irritable bowel syndrome adult respiratory distress syndrome or chronic obstructive pulmonary disease. | SYNTEX (U.S.A.) LLC | 2003-09-11 | — | — | US | disclosed |
| WO-2002064594-A2 | 6-SUBSTITUTED PYRIDO-PYRIMIDINES | F. HOFFMANN-LA ROCHE AG (CH) | 2002-08-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070135458-A1 | 6-Substituted pyrido-pyrimidines | P2RX6, P2RX1, P2RX7 | FGFR1 1580/4885PDGFRB 423/4885PDGFRA 506/4885 |
| US-20030171584-A1 | Treating p38 mediated disorders such as arthritis, Crohns disease, irritable bowel syndrome adult respiratory distress syndrome or chronic obstructive pulmonary disease. | ARRB1, MAPK1, MAPK8 | FGFR1 1258/4885PDGFRB 1928/4885PDGFRA 2189/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.